1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Bora Pharmaceuticals Co Ltd

Bora Pharmaceuticals Co Ltd

2.50
USD
-3.20
(-56.12%)
0.09EPS
33.41P/E
1.63BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.29
0.52
0.55
0.65
0.78
2.75
2.85
3.13
10.49
17.91
23.58
28.52
30.47
30.89
Basic EPS, GAAP
0.01
0.04
0.08
0.06
0.03
0.89
0.57
1.01
1.6
2.38
5.03
6.3
4.78
2.44
Free Cash Flow per Basic Share
-1.37
- -
-0.04
-0.07
0.01
0.26
-0.87
0.04
1.87
3.09
5.29
0.48
5.6
3.1
Dividend per Share
- -
- -
0.03
0.03
0.05
0.03
0.16
0.14
0.23
0.41
1.03
2.02
2.32
- -
Book Value per Share
0.79
1.03
1.08
1.1
1.27
2.47
3
4.26
5.37
7.74
14.97
20.71
24.21
23.75
Tangible Book Value per Share
0.78
1.02
1.07
1.09
1.27
2.47
2.96
4.25
5.08
4.07
5.62
8.49
14.38
10.5
Basic Weighted Avg Shares
316
418
434
433
460
499
537
575
467
586
602
611
624
633
Sales/Revenue/Turnover
93
218
238
283
358
1,372
1,529
1,800
4,900
10,494
14,200
17,427
19,014
19,557
Operating Margin (%)
2.15
11.75
7.97
10.79
5.2
13.65
22.55
12.56
21.35
18.32
36.97
21.28
17.33
15.42
Depreciation Expense
3
15
16
20
21
111
120
141
210
325
606
1,026
1,087
1,124
Net Income, GAAP
4
17
34
25
14
443
305
578
750
1,392
3,030
3,853
2,981
1,547
Effective Tax Rate (%)
- -
17.76
4.14
11.31
13.75
8.61
6.25
2.85
26.78
23.83
24.41
19.25
15.72
30.5
Profit Margin (%)
4.18
7.62
14.16
8.67
3.92
32.27
19.95
32.14
15.3
13.26
21.34
22.11
15.68
7.91
Working Capital
125
83
319
244
393
639
689
340
951
1,745
2,375
9,569
6,017
5,578
LT Debt
220
416
290
199
182
471
1,109
1,483
1,334
4,634
3,487
15,070
12,505
14,067
Total Equity
317
446
468
474
632
1,321
1,654
2,465
3,153
5,140
11,766
14,923
17,472
17,535
Return on Invested Capital (%)
- -
2.82
2.07
3.57
2.06
32.67
12.93
14.1
14.19
15.91
25.81
16.63
7.89
5.84
Return on Capital (%)
- -
2.83
4.59
3.77
2
33.21
12.82
14.24
14.71
16.17
21.13
16.33
9.55
5.06
Return on Common Equity (%)
2.29
4.35
7.36
5.22
2.57
45.74
20.51
28.09
26.69
36.24
44.52
35.24
21.17
11.41

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,723
4,566
7,751
LT Borrowings
11,796
12,319
13,314
LT Finance Leases
709
664
752
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
635
637
637
Market Capitalization
- -
65,091
51,985

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
19,338
19,812
24,396
Cash, Cash Equivalents & STI
5,137
4,890
8,490
Accounts Receivable, Net
8,790
9,193
9,449
Inventories
3,410
3,710
4,184
Total Current Liabilities
13,321
14,338
18,817
Payables & Accruals
- -
- -
- -
ST Debt
5,723
4,566
7,751
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
48.16%
52.75%
17.08%
Free Cash Flow
580.63%
896.65%
1,093.5%
Net Income, GAAP
328.5%
47.5%
-22.61%
Sales/Revenue/Turnover
71.18%
70.72%
9.11%
Total Cash Common Dividend
103.83%
85.06%
17.53%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,857
4,417
5,027
5,746
17,427
2025
4,480
4,868
4,806
4,861
19,014
2026
4,001
5,889
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.18
1.79
2.78
0.98
6.3
2025
2.26
0.99
1.02
0.52
4.78
2026
0.04
0.87
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2.02
2025
- -
- -
- -
- -
2.32
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pao Hsi Sheng
Full Time Employees
2,255
Sector
Health technology
Industry
Pharmaceuticals: other
Address
No. 2, Ruiguang Road Taipei TP Taiwan 114
IPO Date
Oct 1, 2014
Website
bora-corp.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Bora Pharmaceuticals Co., Ltd. engages globally in the research, development, production, distribution, and sale of diverse pharmaceutical products. The company operates through distinct divisions including its Commercial Sales arm, the Contract Development and Manufacturing Organization (CDMO) segment, and various other business ventures. It produces and markets a broad portfolio of prescription, over-the-counter, and specialized branded medications, alongside generic drugs. Furthermore, Bora offers comprehensive contract development and manufacturing solutions, encompassing pharmaceutical formulation, clinical and commercial scale production, advanced packaging with serialization, analytical and microbiological testing, and regulatory compliance support. The company has strategically expanded its footprint, notably through the 2024 acquisition of Upsher-Smith Laboratories, bolstering its U.S. market presence and generic drug capabilities. This was further enhanced by the October 2024 acquisition of Pyros Pharmaceuticals, which expanded its focus on rare disease treatments, including the launch of VIGAFYDE™ for infantile spasms. Bora has also made a significant investment in Tanvex Biopharma, combining biomanufacturing facilities to establish a robust global platform for biologics CDMO services, and acquired a sterile injectable manufacturing facility in Baltimore, Maryland, to boost fill/finish capabilities for large molecules. Additionally, it provides health supplements and skincare products. Its distribution network reaches clinics, pharmacies, and drugstores directly, while also supplying medical centers and hospitals through distributors across numerous international markets. Bora Pharmaceuticals Co., Ltd. was established in Taipei City, Taiwan, in 2007.